Big Pharma’s Big Burden in the Climate Fight: Managing Supply Chain in the Midst of Uncertain Disease Proliferation

Zika. Malaria. Dengue. West Nile. The common denominator? Vector-based transmission. Discussions on the manifestation and regulation of climate change typically center on reductions in greenhouse gas emissions and firm-level abatement costs. Rarely does the debate highlight the implication of rising temperatures on vector-borne disease burden and, importantly, the pharmaceutical industry’s operating and business models.